Hidroferol Hebdomadaire (Calcifediol Monohydrate)

Hidroferol Hebdomadaire is used to address insufficient vitamin D levels and to maintain mineral homeostasis.

• Prevention of vitamin D deficiency in individuals at risk (e.g., limited sun exposure, winter months).
• Treatment of documented vitamin D deficiency to raise serum 25‑hydroxyvitamin D concentrations.
• Support of calcium and phosphate absorption in patients with osteomalacia or rickets risk.
• Adjunctive therapy for osteoporosis management when combined with calcium supplementation.
• Maintenance of adequate vitamin D status in elderly populations.

• Calcifediol monohydrate is the 25‑hydroxy metabolite of vitamin D3. After oral absorption, it circulates bound to vitamin‑D‑binding protein and is converted by 1α‑hydroxylase in the kidney to calcitriol, the hormonally active form. Calcitriol binds to the nuclear vitamin D receptor (VDR) in target cells, regulating gene transcription that enhances intestinal absorption of calcium and phosphate and modulates bone remodeling. The increase in serum 25‑hydroxyvitamin D provides a readily available substrate for rapid activation when physiological demand rises.

Like other vitamin D analogues, Hidroferol Hebdomadaire may be associated with occasional adverse reactions.

Common

• Mild gastrointestinal discomfort such as nausea or abdominal bloating.
• Transient headache or fatigue.
• Slight increase in serum calcium without clinical symptoms.

Serious

• Hypercalcemia presenting with polyuria, polydipsia, or cardiac arrhythmia.
• Hypercalciuria leading to kidney stone formation.
• Allergic skin reactions, including rash or urticaria.

Before using Hidroferol Hebdomadaire, certain safety considerations should be reviewed to minimize risk.

• Assess baseline serum calcium and 25‑hydroxyvitamin D levels, especially in patients with renal or parathyroid disorders.
• Use caution in individuals with a history of hypercalcemia, sarcoidosis, or granulomatous diseases.
• Monitor calcium status periodically during long‑term weekly use.
• Adjust dose or discontinue if signs of hypercalcemia develop.
• Pregnant or breastfeeding women should consult a healthcare professional before initiating therapy.
• Patients with severe liver disease may have altered metabolism of calcifediol.

Calcifediol can affect the activity of several other medicines; awareness of these interactions helps ensure safe co‑administration.

Avoid

• Concomitant use with thiazide diuretics that increase calcium reabsorption, raising hypercalcemia risk.
• High‑dose vitamin D or calcium supplements that may lead to excessive calcium levels.
• Certain anticonvulsants (e.g., phenytoin, phenobarbital) that accelerate vitamin D catabolism, reducing efficacy.

Use with caution

• Corticosteroids, which can impair calcium absorption and may require monitoring of vitamin D status.
• Bisphosphonates, where combined therapy should be coordinated to avoid over‑suppression of bone turnover.
• Mineral oil or cholestyramine, which may reduce oral absorption of calcifediol.